SCHEMBL1320804

SCHEMBL1320804

O=C1Nc2cc(Cl)ccc2C1(Cc1cccc(Cl)c1)NC1CCC(O)CC1

nearest known ligand 0.59

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 20/20 0.59
TP53 P04637 6/20 0.47
MDM4 O15151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1321657 0.95 MDM2 (0.64) MDM2TP53
SCHEMBL1319613 0.90 MDM2 (0.62) MDM2TP53
SCHEMBL1321793 0.90 MDM2 (0.59) MDM2TP53
SCHEMBL1319587 0.89 MDM2 (0.61) MDM2TP53
Bicarbonate SCHEMBL3251541 0.88 MDM2 (0.57) MDM2TP53
SCHEMBL1320070 0.84 MDM2 (0.57) MDM2TP53
SCHEMBL3251552 0.84 MDM2 (0.52) MDM2TP53
SCHEMBL1322400 0.81 MDM2 (0.48) MDM2TP53MDM4
SCHEMBL1322402 0.81 MDM2 (0.48) MDM2TP53MDM4
SCHEMBL1322399 0.80 MDM2 (0.47) MDM2TP53MDM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8058269-B2 rac-6-chloro-3-(3-chloro-benzyl)-3-(3-isopropoxy-phenylamino)-1,3-dihydro-indol-2-one; murine double minute (MDM2 ) oncogene inhibitor; feedback control loop of p53 mutant cells; inhibit the interaction between p53 and MDM2 proteins HOFFMAN-LA ROCHE INC. (US) 2011-11-15 US disclosed
US-8058269-B2 rac-6-chloro-3-(3-chloro-benzyl)-3-(3-isopropoxy-phenylamino)-1,3-dihydro-indol-2-one; murine double minute (MDM2 ) oncogene inhibitor; feedback control loop of p53 mutant cells; inhibit the interaction between p53 and MDM2 proteins HOFFMAN-LA ROCHE INC. (US) 2011-11-15 US disclosed
US-8058269-B2 rac-6-chloro-3-(3-chloro-benzyl)-3-(3-isopropoxy-phenylamino)-1,3-dihydro-indol-2-one; murine double minute (MDM2 ) oncogene inhibitor; feedback control loop of p53 mutant cells; inhibit the interaction between p53 and MDM2 proteins HOFFMAN-LA ROCHE INC. (US) 2011-11-15 US disclosed
EP-2066318-B1 OXINDOLE DERIVATIVES AS ANTICANCER AGENTS HOFFMANN LA ROCHE (CH) 2010-05-12 EP disclosed
EP-2066318-B1 OXINDOLE DERIVATIVES AS ANTICANCER AGENTS HOFFMANN LA ROCHE (CH) 2010-05-12 EP disclosed
US-20080081810-A1 OXINDOLE DERIVATIVES CHEN LI 2008-04-03 US disclosed
US-20080081810-A1 OXINDOLE DERIVATIVES CHEN LI 2008-04-03 US disclosed
US-20080081810-A1 OXINDOLE DERIVATIVES CHEN LI 2008-04-03 US disclosed
WO-2008034736-A2 OXINDOLE DERIVATIVES AS ANTICANCER AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2008-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081810-A1 OXINDOLE DERIVATIVES CCNY, CCNI, RPS4Y1 MDM2 441/4885TP53 219/4885MDM4 1191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.